www.genfit.com

MAJOR PROGRESS IN THE DEVELOPMENT OF GFT505: FILING OF A CLINICAL TRIAL APPLICATION IN NASH WITH THE FDA

- **Very positive consulting meeting with the FDA**
- **Official filing of a Phase IIb trial in the United States**

Lille (France), Boston (Massachusetts, United States), June 20, 2012 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announced, at the BIO International Convention, that it will file an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) before the end of June 2012, to enable the conduct of a Phase IIb trial with GFT505 in NASH* in the United States.

This IND application follows a very positive consulting meeting with the FDA on the entire GFT505 dossier, on the Phase IIb study, and more generally on the development plan for GFT505 in NASH.

The Phase IIb trial concerned by the IND application is an international multi-center study involving 75 clinical investigation centers, including 20 centers in the US.

«*Our fruitful discussions with members of the FDA's gastro-intestinal division further convinced us of the potential of GFT505 as a first-in-class medicine for the treatment of NASH, a growing medical need that is still unmet on both sides of the Atlantic. This news should facilitate our discussions with partners that are interested in the development of GFT505 in NASH.*» declared J**ean-François Mouney, Chairman and CEO of GENFIT**.

***About NAFLD and NASH:**
In parallel with the current pandemic of diabetes and obesity, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing considerably. NAFLD is believed to affect between 80 and 100% of diabetic patients, and progresses to non-alcoholic steatohepatitis (NASH) in 20-50% of cases. This serious liver disease can further progress to cirrhosis and liver cancer. There is currently no approved treatment for NAFLD/NASH, and the portfolio of products in the advanced stages of development is limited.

About GENFIT:
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.
GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT
Jean-François Mouney – CEO & Chairman of the Management Board
+33 (0)3 2016 4000

MILESTONES – Press Relations
Bruno Arabian
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – barabian@milestones.fr